Targacept to Present at the Cowen and Company 33rd Annual Health Care
Cowen Group Healthcare Conference 2013
WINSTON-SALEM, N.C. -- February 26, 2013
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A.
Hill, President and Chief Executive Officer, is scheduled to present at the
Cowen and Company 33^rd Annual Health Care Conference at The Boston Marriott
Copley Place in Boston, Massachusetts on Tuesday, March 5, 2013 at 8:00 a.m.
The presentation will be webcast and accessible from the Investor Relations
page of Targacept’s website, www.targacept.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15 minutes
prior to the scheduled start time. An archived version of the webcast will be
available for replay on the Investor Calendar section of the Investor
Relations page of Targacept’s website for at least two weeks following the
Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM)
for difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
multiple Phase 2 product candidates, all representing first-in-class
opportunities. Targacept leverages its scientific leadership and diverse
pipeline to attract significant collaborations with global pharmaceutical
companies. For more information, please visit www.targacept.com.
Building Health, Restoring Independence^®
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.